Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00731627 · ClinicalTrials.gov registry record · Phase 3
Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial
A Phase 3 study of Subarachnoid Haemorrhage, sponsored by Cambridge University Hospitals NHS Foundation Trust.
- Completed
- Registry status
- Phase 3
- Development phase
- 803
- Enrollment target
- 2
- Study locations
NCT00731627: Completed Phase 3 study of Subarachnoid Haemorrhage, sponsored by Cambridge University Hospitals NHS Foundation Trust.
NCT00731627 is a Phase 3 study of Subarachnoid Haemorrhage that has completed, run by Cambridge University Hospitals NHS Foundation Trust. The registered enrollment target is 803 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00731627, a Phase 3 study of Subarachnoid Haemorrhage, has completed, sponsored by Cambridge University Hospitals NHS Foundation Trust.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 803 participants
- Enrollment target
- 2
- Study locations
Study Summary
Intracranial bleeding from ruptured blood vessels (called a subarachnoid haemorrhage -SAH) affects 7000 patients each year in the UK and is a source of considerable death and disability, even in young adults. Recent observations indicate that these bleeds can cause reduced cerebral blood flow which leads to a bad outcome. High rates of death and disability occur, and are particularly prevalent when low cerebral blood flow results in stroke. Prevention of cerebral artery spasm and improvement in blood vessel reflexes are the target of modern therapy. Candidate drugs include statins which have an impeccable safety record and multiple potential beneficial actions (improve cerebral blood flow, reduce inflammatory processes, reduce adverse blood coagulation) following SAH. The investigators plan to use a statin, Simvastatin (40 mg) to improve cerebral blood flow and reduce inflammation. We have already completed a phase 11 study (n=80) which demonstrated potential benefits for acute statin therapy following SAH, and the investigators now wish to conduct a multi-centre phase 111 study to explore any potential clinical benefits in a larger population (n=1600). The purpose is to see whether the positive effects of statins seen in our phase II study translate into clinical benefits - both short term (e.g. reduced need for intensive care) and long term (outcome and wellbeing at 6 months).
Conditions Studied
Interventions
- DRUG placebo
- DRUG simvastatin
Study Locations (2)
Florida
- Dept of Neurological Surgery, University of Florida - Gainesville
- Mayo Clinic - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 803 participants |
| Start Date | 2007-01 |
| Est. Completion | 2014-02 |
| Phase | Phase 3 |
What the finished NCT00731627 record still lists
NCT00731627 is an interventional study that assigns participants to a tested intervention. The registered 803 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 1 condition, with Subarachnoid Haemorrhage appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00731627 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00731627 about?
NCT00731627 is a clinical study titled "Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial". Intracranial bleeding from ruptured blood vessels (called a subarachnoid haemorrhage -SAH) affects 7000 patients each year in the UK and is a source of considerable death and disability, even in young adults. Recent observations indicate that these bleeds can cause reduced cerebral blood flow which ...
What is the current status of trial NCT00731627?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 803 participants. The study started on 2007-01. Estimated completion is 2014-02.
What conditions does trial NCT00731627 study?
This clinical trial studies the following conditions: Subarachnoid Haemorrhage.
What interventions are being tested in trial NCT00731627?
The interventions under investigation include: placebo (DRUG), simvastatin (DRUG).
Who is sponsoring clinical trial NCT00731627?
This trial is sponsored by Cambridge University Hospitals NHS Foundation Trust, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00731627 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00731627's enrollment target sits among peer trials
803 413th of 2000 higher than 1,588 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04423211 · 804 participants · Phase 3
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- NCT06522022 · 804 participants · NA
PTSD Screening in Pregnant Black Women
- NCT03524430 · 801 participants · NA
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia